SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C.  20549

                        AMENDMENT NO. 1 TO FORM 10-QSB
                               ON FORM 10-QSB/A

                     FOR QUARTER ENDED SEPTEMBER 30, 1998

                QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
                  OF THE SECURITIES AND EXCHANGE ACT OF 1934

                        COMMISSION FILE NUMBER 1-10768
                                               -------


                      MEDIWARE INFORMATION SYSTEMS, INC.
            (Exact name of registrant as specified in its charter)

     New  York                                        11-2209324
  (State  of  other  Jurisdiction  of              (I.R.S.  Employer
  incorporation  or  organization)              Identification  Number)


  1121  Old  Walt  Whitman  Road
  Melville,  New  York                                  11747-3005
  (Address  of  Principal  Executive  Officer)          (Zip  Code)



                                (516) 423-7800
             (Registrant's telephone number, including area code)




Indicate  by  check  mark  whether  the  registrant  (1) has filed all reports
required  to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934  during  the  preceding  12  months  (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to such
filing  requirements  for  the  past  90  Days.     Yes      X       No ______
                                                          ------

As  of  September 30, 1998, there were 6,051,000 shares of Common Stock, $0.10
par  value,  of  the  registrant  outstanding.

<PAGE>

MEDIWARE  INFORMATION  SYSTEMS,  INC.

                                     INDEX

Part  I.     Financial  Information                                       Page
                                                                          ----


ITEM  2.     Management's  Discussion  and  Analysis  of  Financial
             Condition  and  Results  of  Operations                         2


Signature  Page                                                              7


This  Amended Quarterly Report on Form 10QSB/A is filed to provide information
under  the  caption "Year 2000 Issues."  No other information has been changed
or  updated  from  the  original filing on November 20, 1998.  For more recent
information  regarding  "Liquidity and Capital Resources," you are referred to
the  Company's  Proxy  Statement  dated  January  11,  1999.



<PAGE>

ITEM    2.     MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
               RESULTS  OF  OPERATIONS.

FORWARD-LOOKING  STATEMENTS:

     Certain  statements  made  in  this  report  are or imply forward-looking
statements.       Such forward looking statements are not guarantees of future
performance and are subject to risks and uncertainties that could cause actual
results  to  differ  materially  from  those  expressed  or  implied  in  the
forward-looking  statements.      Certain of these risks and uncertainties are
expressed  in  the  Risk  Factors  discussed in the Prospectus included in the
Registration  Statement  on  Form  SB-2, File No.  333-18277, especially those
under  the  headings    "Working  Capital  Deficiency; Restrictive Covenants,"
"Variability  of  Operating  Results,"    "Hospital  Purchase  Procedures,"
"Acquisition,"  "Competition,"    "Technological  Obsolescence;  Marketing and
Acceptance  of  New  Products,"    "Product  Protection"    and    "Government
Regulation."

RESULTS  OF  OPERATIONS:  AS  OF  NOVEMBER  20,  1998

     During  the  quarter  the  Company  acquired  Informedics,  Inc.
("Informedics").    Informedics  develops,  markets  and  supports  a  line of
stand-alone computer-based management information systems for use in the blood
bank  and  clinical  departments  of hospitals.  Additionally, Informedics has
been  developing a Web-enabled software system technology called IntraMed.net.
This internet/intranet oriented software is intended to provide the ability to
extract  data  from installed legacy computer systems and then store, download
or manipulate the data.  While no assurances can be made, the Company believes
that Informedics' Web-enabling technology, when implemented and sold to future
and  existing  customers,  will  expand  the  reach  of  the  three  clinical
departments  (Blood  Bank,  Pharmacy  and  Surgical  Suite) Mediware currently
addresses.    The  acquisition  was  completed  in  September,  1998,  and was
accounted  for  as  a  purchase.    The  Company's  operating  results include
Informedics  from  the  date  of  acquisition  which  consisted of revenues of
$47,000  and  operating  expenses  of  $40,000.      Additionally, the Company
recorded  a  one-time  acquisition related charge of $4,553,000 for in-process
research  and  development  related  to  the  estimated  fair  value  of  the
IntraMed.net  technology.

     Total Company revenues  increased  by 23.6% or $1,169,000  for  the first
three  months  of fiscal  1999  as compared to the same period in fiscal 1998.
This  increase was impacted by all product lines but was significantly related
to  revenue  gains  in  the  Company's  Blood  Bank  Division.

     System  sales  increased  by  56.9% or $1,060,000 in the first quarter of
fiscal  as  compared  to  the  same period in the prior year.   For the period
ended  September  30,  1998  the increase is primarily due to increased system
sales  in  the  Company's  Pharmacy  and  Blood  Bank  Divisions.

     Services  revenues  increased 3.5% or $109,000 to $3,205,000 in the first
three months of fiscal 1999 as compared to $3,096,000 for the same period last
year.    The  increase  is  primarily due to increased service revenues at the
Company's  Hemocare  Division.

     Cost  of  systems  includes the cost of computer hardware and sublicensed
software  purchased  from  computer  and software manufacturers by Mediware as
part  of  its  complete  system  offering.  These costs can vary as the mix of
revenue  varies  between  high  margin  proprietary  software and lower margin
computer  hardware  and  sublicensed software components. Cost of systems were
30.8%  of  related  system  sales for the first three months of fiscal 1999 as
compared  to 35.7% of related system sales for the same period in fiscal 1998.
Cost  of  systems  increased  by  35.5% or $236,000 from $665,000 in the first
quarter  fiscal  1998  to  $901,000  in  the same period in fiscal 1999.  This
increase  in  cost is principally due to the change in mix between proprietary
licensed  software  (which  is  at  a  higher  gross  margin)  and third party
software/hardware  (which  has  a  lower  gross  margin)  within  the Pharmacy
division.

     Cost  of  services  includes the salaries of client service personnel and
communications  expenses along with the direct expenses.  The cost of services
will vary with technical employee activity changes between client services and
software development. Cost of services increased $160,000 from $747,000 in the
first  three  months of fiscal 1998 as compared to $907,000 in the same period
of  the  current fiscal year.   Cost of services were 28.3% of related revenue
for the three months ended September 30, 1998 vs. 24.1% of related revenue for
the  same  period  a year earlier. This increase in cost primarily reflects an
increase  in  technical field installation activities related to the Company's
Pharmacy  division.

     Software  development  costs include salaries, consulting, documentation,
office  and  other  expenses  incurred  in  product  development  along  with
amortization  of  software  development  cost.    Software  development  costs
increased  $79,000  or 13.5% from $584,000 in the first three months of fiscal
1998  to  $663,000  in the same period in fiscal 1999.  Expenditures  (amounts
including  both  capitalized  and  non-capitalized  expenditures and excluding
capitalized  software  amortization)  for  software  development for the first
three  months  of  fiscal  1999  were  approximately   $991,000 as compared to
$709,000  in  the  first three months of fiscal 1998.  Spending on development
has  increased  among  all company divisions but is principally focused on the
Company's  Pharmacy  division's  enhancements  to  its WORx product line.  The
Company  expects to continue this level of development spending with increased
focus  on  continued  product  enhancements  and  integration  of  Web-based
communications  technology.

     Selling,  general and administrative expenses include marketing and sales
salaries,  commissions, travel and advertising expenses.  Also included is bad
debt  expense;  legal,  accounting  and  professional fees; salaries and bonus
expense  for  corporate,  divisional,  financial  and  administrative  staff;
utilities,  rent,  communication  and other office expenses; and other related
direct  administrative expenses.  Selling, general and administrative expenses
increased  by   $417,000 or 19.0% from $2,191,000 in the first three months of
fiscal 1998 to $2,608,000 in the same period in fiscal 1999.  This increase in
cost is due to higher communications, travel, administrative, marketing, legal
and  professional  costs.    This  increase reflects the cost of  managing and
growing  the  Company.      Additionally,  the  increase  reflects  the higher
commission  costs  related  to  increased  sales  volume.

     Net  interest  expense  decreased    $59,000  or 53.2% in the first three
months  of  fiscal  1999  vs. the same period a year ago.  For the three-month
period  the  reduced interest expense is due to the $600,000 decrease of notes
payable  from  September  30,  1997  to  September  30,  1998.

     Net earnings were directly affected by the $4,553,000 one-time charge for
in-process  research  and  development  resulting in a net loss of $3,706,000.
Excluding  this  one time charge, net earnings for the quarter ended September
30, 1998 increased by 36.0% or $224,000 from $623,000 for the first quarter of
fiscal  1998  to  $847,000  for  the  same  period  in  fiscal  1999.

LIQUIDITY  AND  CAPITAL  RESOURCES:  AS  OF  NOVEMBER  20,  1998

     The Company's cash and cash equivalent position at September 30, 1998 was
$4,897,000, an increase of $216,000 from June 30, 1998.  At September 30, 1998
the current ratio was 1.1:1.   Current liabilities include $4,450,000 in notes
payable,  of  which $3,600,000 is owed to Continental Healthcare Systems, Inc.
("Continental").   The Continental note is due November 30, 1998.  The balance
in  notes  payable  at the end of September 30, 1998 was owed to two directors
and  another  person.     The Company is currently in negotiation with several
leading  institutions  seeking to obtain favorable terms in borrowing rates on
refinancing  portions or all of the Continental note.  While no assurances can
be  made,  it  is  anticipated  that  this  promissory  note  payment  will be
substantially financed through a commercial long-term loan at rates comparable
to  the existing note.  In addition to refinancing of the promissory note, the
Company  will review other financing needs and general cash requirements on an
on-going  basis.    The Company may require additional sources of liquidity to
fund  potential  acquisitions,  expanded  research and development costs along
with  other  financing  needs.

<PAGE>
YEAR  2000  ISSUES:  AS  OF  JANUARY  27,  1999

Pharmacy  Division
------------------

     WORx:     The problems of  date-protocol  compatibility in  the Year 2000
are somewhat different for each of the Company's software information systems.
In  the  case  of  the  Pharmacy  division's  WORx  system, this client/server
software  application  has been designed by the Company to meet conditions for
date protocol compatibility by the Year 2000.  As a client/server application,
several  layers  of  software  manipulate data.  This data is stored within an
Informix  relational  database, which supports dates beyond December 31, 1999.
The WORx application runs under Microsoft Windows, uses it's date formats, and
will  support  dates beyond December 31, 1999. Although WORx has been designed
to be Y2K compatible, Mediware is currently developing a certification process
for  the product, which it hopes to complete during the first quarter of 1999.

     Digimedics  XA: The Company's Pharmacy division has completed development
of its Y2K compatible Digimedics XA pharmacy system.  This software,  version 
3.0, is  currently in internal  alpha  testing, and if testing is successful, 
will  be  made  available  to  its  beta  clients  during  the  first  quarter
of 1999.

     Pharmakon  "Mini"  (Unix based):  The  Company's  Pharmacy  division has 
completed both  internal  and  external  testing of its "Unix based" Pharmakon
pharmacy system  and plans to make this new Y2K  compatible release,  version 
3.5, available to its installed client  base during the first quarter of 1999.

     Pharmakon "Mainframe": The Company's Pharmacy division has also completed
its own internal testing of its "mainframe based" Pharmakon  pharmacy  system.
This Y2K  compatible  software, version 5.0, is currently in external beta
testing, and if testing is successful, will be made available to its installed
client base  during  the  first  quarter  of  1999.

     These  three  new  software release  versions  (Digimedics XA,  Pharmakon
"Mini", and  Pharmakon  "Mainframe"),  which  incorporate  the  upgrade of the
Company's application  software systems necessary for Year 2000 compatibility,
will be distributed  to customers under the Company's normal software  support
contract procedures.  The Y2K compatible software application revision upgrades
will be provided  by  the  Company without cost to the hospital; however,  the
computer and  operating  system platforms  of  a number of hospitals  will not
accommodate the  Y2K compatible software revisions distributed by the Company,
and these hospitals must acquire, and bear the cost  of  new computer hardware
and associated  operating  systems  and  pharmacy  data  bases.

<PAGE>

JAC
---

     The  Company's  United  Kingdom  subsidiary,  JAC,  started early in 1998
notifying  its  clients  concerning appropriate steps they must take to ensure
their  entire computer system meets all aspects of the National Health Service
(NHS)  directive for Y2K compatibility.  The NHS directive requires each Trust
(hospital)  to  have  either  upgraded  to  be  Y2K compatible, have a plan to
upgrade,  or  have  contingency  plans, ready by 12/31/1998.  Although the JAC
stock control pharmacy system has been internally and externally certified Y2K
compatible,  JAC has been notifying all of its clients in writing, verbally by
telephone,  using  articles  in  its  newsletter, and raising the issue at its
National and Local User Group meetings, that some clients will have to upgrade
certain components of their computer hardware and associated operating systems
and  pharmacy  data  bases  to  ensure  full  compatibility.

Surgiware
---------

     The  Company's  Operating  Room  division  has completed its own internal
testing  to  determine  whether  the  application  meets  Y2K  compatibility
standards,  and  as  a  result of the testing believes that the operating room
information  system  meets  the conditions for date-protocol readiness.  A new
Year  2000  compatible  revision  is being offered to hospitals as part of the
normal support procedures of the Company. However, the computer platforms of a
number  of hospitals will not accommodate the updates necessary to become Year
2000  ready,  and  these hospitals must bear the cost of new computer hardware
and  associated  operating  systems  and  operating  room  data  bases.

Blood  Bank  Division
---------------------

     Hemocare:    In the case of the Company's Hemocare blood bank system, the
Company  has  completed  its own internal testing of its application software,
release 5.2, which is ready for release to customers.  Mangement believes this
new  Hemocare  release  meets  Y2K  compatibility  standards.  The application
software runs under a UNIX based operating system and the application software
was  designed  utilizing absolute Julian dates. The absolute Julian start date
for the Hemocare blood banking application is Jan.1, 1968.  That specific date
is  known as Julian day 1.  Each day after Jan. 1, 1968 causes the Julian date
to  increase  by  one.  Therefore, Feb. 1, 1968 has a Julian date of 32, since
that was the 32nd day after Jan. 1, 1968. On Jan. 1, 1969, the Julian date was
367,  representing  367 total days since Jan. 1, 1968, including the leap day.
In  a  similar  fashion,  the  Julian date for Jan. 1, 2000 will simply be one
greater  than  the  Julian date for Dec. 31, 1999.  The fact that the last two
digits of the year 2000 are 00 will not impact Hemocare's date calculations or
comparisons,  since  the  dates  are  not  stored in a complex form made up of
years,  months,  and  days.  However,  it  may  be  necessary  for some client
hospitals  to  upgrade  their  computer  platforms,  and  associated operating
systems,  or  the  BIOS  of  their  current  hardware,  to be Year 2000 ready.

<PAGE>

     Informedics LifeLine:  The Company has also completed internal testing of
a  new  version  of  the  LifeLine  product,  version 4.3, which, based on the
testing,  meets  Y2K  compatibility issues. However, because older versions of
the  LifeLine  product  now  in  use  are not Year 2000 compatible, it will be
necessary  for  Informedics'  customers  to upgrade their systems with the new
version 4.3 release. The Company has contacted all current and prior customers
of  versions  of  the LifeLine product to inform them of the actions they must
take  in  order  to  achieve  Year  2000  compatibility.

Informedics  StarPath:   The Company has completed testing of a new version of
its  StarPath  pathology  product,  version  6.4C,  which  now  meets  Y2K
compatibility  issues.  This  product  will  be made available to all StarPath
customers  during  the  month  of  April  1999.

Internal
--------

     The Company has assigned a project team to examine relationships with all
of  its  vendors,  including suppliers of both IT and non-IT Systems regarding
Y2K  readiness.    Any  vendor  that  supplies  the  Company with information,
processes  information  for  the  Company,  and  all  internal systems using a
microprocessor  will  be queried as to their ability to meet Y2K compatibility
guidelines.  The  Company  expects  to complete its initial assessment of such
areas during the first quarter of 1999. Following such initial assessment, the
Company  will  undertake  Year  2000  remediation  and  testing  of  these
applications. The Company cannot determine, at this time, the number of non-IT
systems  that will require remediation; however, based on the current state of
its  investigation, the Company knows of noYear 2000 problems which it expects
to  become  material.

General
-------

     The  Company  is  performing  Year 2000 date-protocol tests and providing
remedial action for all of its products along with examining its relationships
with  third  parties.  This  review  includes suppliers of hardware, data base
providers, network operating systems and utility programs, whose failure to be
Year  2000 compatible could have a material adverse effect on the Company. The
incremental  costs  to the Company in achieving Year 2000 compatibility cannot
be accurately predicted and will depend upon the timely completion of tasks by
both  the  Company  and  its  customers.    The  Company must ensure Year 2000
compatible, third party components, timely release of its upgraded application
software,  databases,  its  ability  to  schedule  and  install Y2K compatible
upgrades,  and  other factors.  Customers must ensure that hardware, operating
systems,  computer BIOS, and networking software are Year 2000 compatible, and
have  the  ability to schedule and install upgraded software versions provided
by  the  Company.  Failure to successfully meet any or all of these conditions
could  have  a  material  adverse  effect on the Company's business, financial
condition  and  results  of  operations.

     The suppliers of the computers, operating systems and data bases necessary
to operate  the  current  versions  of  the  Company's  software products have
indicated to the  Company  that those products either are Year 2000 compatible
or theywill  be  by  the  end of 1999. The Company has conducted tests of such
computers, operating  systems  and  data  bases  with  the  Company's products
now being marketed  and currently  has no reason to believe that the Company's
products are  not  Year  2000  compatible  when  operated with such computers,
operating systems  and  data  bases.


<PAGE>

                                  SIGNATURES

     Pursuant  to the requirements of the Securities Exchange Act of 1934, the
Registrant  has  duly  caused  this  report  to be signed on its behalf by the
undersigned,  thereunto  duly  authorized.


                                         MEDIWARE  Information  Systems,  Inc.
                                         -------------------------------------
                                                    (Registrant)



January  27,  1999                    By:                /s/
------------------                     ---------------------------------------
    (Date)                                        John  Esposito
                                           President  and  CEO  and  CFO